Vigonvita Life Sciences Co., Ltd. submitted its monthly return for the period ended 30 April 2026, confirming a stable capital structure and adherence to Hong Kong Listing Rule public-float requirements.

Authorised and Issued Share Capital • Total authorised share capital stood at RMB 167.60 million, unchanged from the prior month. • This comprises 66.68 million H-shares listed on the Stock Exchange of Hong Kong and 100.92 million unlisted ordinary shares, each carrying a par value of RMB 1. • Issued shares mirrored authorised figures, with no share issuances, cancellations, or treasury share movements recorded during the month.

Public Float Status • The company affirmed that its H-share public float met the minimum 25 % threshold mandated by Main Board Rule 13.32B.

Capital Instruments and Corporate Actions • No share options, warrants, convertible securities, or other equity-linked instruments were outstanding or issued. • There were no repurchases, redemptions, or other alterations to share capital.

Regulatory Compliance • The filing, dated 07 May 2026 and signed by Board Secretary Guo Ting, includes standard confirmations that all listing, legal and regulatory obligations have been fulfilled.